Sequenom CEO Buys $97K Worth of Co.'s Stock This Month As Shares Rally | GenomeWeb
NEW YORK (GenomeWeb News) - Sequenom CEO Harry Stylli bought 13,313 shares of the company's stock at an average price of $1.86 per share for total proceeds of $24,964 on Aug. 11, according to documents filed with the Securities and Exchange Commission.
 
Since Aug. 7, he purchased 53,700 shares for total proceeds of $96,565. He currently owns 54,700 shares of Sequenom stock.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.